Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Migraines and depression risk: Study finds link

According to a new Canadian study, people who get attacks of migraine may be at a higher risk for developing clinical depression.

27 Nov 2011

Deep brain stimulation benefits highly treatment resistant patients with major depressive disorder

Results from the first multi-center pilot study of deep brain stimulation (DBS) for major depressive disorder were published online today by the Journal of Neurosurgery. The study, conducted at three research facilities in Canada, was designed to replicate and build upon an earlier study by Dr. Andres Lozano and Dr. Helen Mayberg which was published in the journal Neuron in 2005.

18 Nov 2011

Higher protein load in critical brain regions linked to severe depression in late life

Depression is one of the most common mental disorders in the elderly, but little is known about the underlying biology of its development in older adults.

8 Nov 2011

Top-line results from AstraZeneca and Targacept's TC-5214 Phase 3 studies on MDD

AstraZeneca and Targacept, Inc. today announced top-line results from the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant treatment.

8 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Vanda third quarter total revenues increase to $8.0 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

4 Nov 2011

New e-tool to catch youth depression before it takes hold

Australian researchers will for the first time harness e-technology to develop a customised internet program to identify and arm healthy young people most at risk of depression before the illness takes hold.

1 Nov 2011

'Deep sequencing' technology identifies new target area for depression

Scientists at the Texas Biomedical Research Institute and Yale University have identified a new target area in the human genome that appears to harbor genes with a major role in the onset of depression.

29 Oct 2011

Study: Depressive symptoms linked to negative health risks among asthma patients

People with asthma are more likely to have symptoms of depression. A new study suggests these symptoms are linked to a host of other negative health risks that may lead to a worsening of asthma symptoms and an overall decline in health.

27 Oct 2011

CompCare to distribute innovative lumbar traction DDS belt in the U.S., Canada and Puerto Rico

Comprehensive Care Corporation, which provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the U.S., today announced that it has acquired exclusive distribution rights to an innovative patented product aimed directly at reducing depression in individuals resulting from chronic back pain.

24 Oct 2011

Future-Directed Therapy for patients with major depression

Patients with major depression do better by learning to create a more positive outlook about the future, rather than by focusing on negative thoughts about their past experiences, researchers at Cedars-Sinai say after developing a new treatment that helps patients do this.

20 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

FDA approves NDA for Edgemont's Fluoxetine 60 mg tablet

Edgemont Pharmaceuticals, LLC, a neuroscience focused company, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Fluoxetine Tablets 60 mg.

12 Oct 2011

High consumption of caffeinated coffee appears to reduce risk of depression in women

The risk of depression appears to decrease for women with increasing consumption of caffeinated coffee, according to a report in the September 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Sep 2011

Researchers discover molecular-level changes in brains of women with major depressive disorder

Researchers at the University of Pittsburgh School of Medicine have discovered molecular-level changes in the brains of women with major depressive disorder that link two hypotheses of the biological mechanisms that lead to the illness. Their results, published online this week in Molecular Psychiatry, also allowed them to recreate the changes in a mouse model that could enhance future research on depression.

17 Sep 2011

Longer looks: Unknowns in sports medicine; shackling pregnant prisoners

Medical experts say that multiple futile treatments is all too familiar and points to growing problems in sports medicine, a medical subspecialty that has been experiencing explosive growth. now researchers are questioning many of the procedures, including new ones that often have no rigorous studies to back them up. "Patients come in and say, 'I want the same thing that Tiger Woods had,' " said Dr. McDevitt, the sports medicine orthopedist in Maryland.

9 Sep 2011

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston.

2 Sep 2011

Dad's stress can affect unborn children

Does Dad's stress affect his unborn children? According to the results of a new study in Elsevier's Biological Psychiatry, it seems the answer may be "yes, but it's complicated".

31 Aug 2011

Daily exercise can work as well as second antidepressant drug

Exercise can be as effective as a second medication for as many as half of depressed patients whose condition have not been cured by a single antidepressant medication.

24 Aug 2011

Mood-related brain protein linked to sadness during cigarette withdrawal

Heavy smokers may experience sadness after quitting because early withdrawal leads to an increase in the mood-related brain protein monoamine oxidase A (MAO-A), a new study by the Centre for Addiction and Mental Health (CAMH) has shown. This finding, which was published in the Archives of General Psychiatry, may also explain why heavy smokers are at high risk for clinical depression.

3 Aug 2011